Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis

Summary

The aim of this study is to assess the safety of Stemedica's mesenchymal stem cells in patients with knee osteoarthritis. The route of administration is intraarticular. Safety will be evaluated by AE/SAE incidence and administration tolerance. The subjects will undergo follow-up for 52 weeks. The target population is subjects with knee osteoarthritis (grade II-III in Kellgren-Lawrence scale).

Timeline

Start

2019-08

Primary completion

2020-04

Completion

2020-04

Outcome

Outcome not reported

Stopped: “Sponsor to start with different protocol, postponed due to COVID”

Drugs

Indications